Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review

摘要: Purpose Since 1997, strong incentives have been introduced worldwide to improve access safe and effective medicines addressing the therapeutic needs of children. ACE inhibitors, most prescribed antihypertensive drugs in paediatric population, are one prototype targeted by legislation initiatives. Our purpose assembling this review is evaluate describe current evidence for efficacy safety profile inhibitors population. Methods The authors made a descriptive literature from 1980 2015 using following search terms: hypertension, child, paediatric, (inhibitors), renin–angiotensin aldosterone system, captopril, lisinopril, enalapril, ramipril fosinopril. Results A total 16 studies evaluating were included review. demonstrate that potency decrease systolic and/or diastolic blood pressure with an overall favourable short-term period. More importantly, resulted improvement availability labelling, dosing information inhibitors. However, they failed fulfil several needs: absence long-term data on growth maturation, commercially available child-friendly formulations incomplete evaluation entire hypertension Conclusion Additional efforts needed close gap between labelled indicated use actual drug usage children, especially young neonates children severe renal transplantation or impairment.